Candid Therapeutics, Inc. Sustainability Profile
Candid Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, is dedicated to advancing innovative therapies for patients with unmet medical needs. Founded in 2018, Candid Therapeutics focuses on developing cutting-edge treatments in the fields of neurology and rare diseases, leveraging its expertise in drug discovery and development. The company’s core offerings include a unique portfolio of therapeutic candidates designed to address complex neurological disorders. Candid Therapeutics distinguishes itself through its commitment to precision medicine and patient-centric approaches, aiming to improve outcomes for individuals suffering from debilitating conditions. With a strong market position and a growing reputation for excellence, Candid Therapeutics continues to make significant strides in the biopharmaceutical industry, contributing to the advancement of healthcare solutions.
DitchCarbon Score
How does Candid Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Candid Therapeutics, Inc.'s score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Candid Therapeutics, Inc.'s reported carbon emissions
Candid Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As a result, there are no significant achievements or targets to highlight regarding their carbon footprint or climate commitments. The lack of emissions data and reduction initiatives suggests that Candid Therapeutics may still be in the early stages of developing a comprehensive climate strategy.
How Carbon Intensive is Candid Therapeutics, Inc.'s Industry?
How Carbon Intensive is Candid Therapeutics, Inc.'s Location?
Candid Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Candid Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
